Since the treatment duration was limited to two weeks, it is hypothesized that extended supplementation with B. coagulans Unique IS-2 and B. clausii UBBC-07 post-COVID-19 could further reduce inflammation, modulate the gut microbiota, and help restore normal levels of other biomarkers. One limitation of this study was that CRP was measured using a qualitative method rather than a quantitative one, due to the high patient load in the COVID-19 ward, which made it challenging to manage. This evidence concerns the gene CRP and COVID-19.